Reproducible In Silico Comparison of an ALS-Associated SOD1 Variant and Critical Appraisal of RNA-Based Therapeutic Strategies

Reproducible In Silico Comparison of an ALS-Associated SOD1 Variant and Critical Appraisal of RNA-Based Therapeutic Strategies Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motor neuron degeneration, muscle weakness, and loss of voluntary muscle function. Mutations in the superoxide dismutase 1 (SOD1) gene are associated with inherited forms of ALS and represent important molecular targets for therapeutic research. This study presents a reproducible computational analysis comparing the normal human SOD1 reference transcript (NM_000454.5) with a computationally reconstructed ALS-associated mutation, c.281G>C (p.Gly94Ala). Using Python-based sequence analysis, FASTA comparisons, codon translation, and mathematical calculations, the study identifies a single nucleotide substitution that changes glycine to alanine at protein position 94. The analyzed sequences demonstrate approximately 99.8883% nucleotide identity and 99.3506% protein sequence identity. The research also critically evaluates potential RNA-based therapeutic strategies, including suppression of toxic mutant SOD1, genetic mutation correction, and the proposed restoration of normal protein function through therapeutic messenger RNA (mRNA). Particular attention is given to the biological limitations of protein replacement because SOD1-associated ALS is primarily associated with toxic gain-of-function mechanisms. The study discusses why increasing normal SOD1 protein production alone may not overcome mutant protein toxicity. Supplementary materials include reference and reconstructed FASTA sequences, reproducible Python analysis, mathematical calculations, and comparative research data. This work provides an educational and computational framework for investigating ALS-associated genetic mutations and prioritizing future therapeutic hypotheses. Research limitations: This is an in-silico analysis. No patient-derived samples, therapeutic mRNA candidates, laboratory experiments, animal studies, or clinical trials were conducted. No therapeutic efficacy is claimed. Author: Rami M. Alkhaleeli Affiliation: Alkhaleeli BioAI LLC, Yukon, Oklahoma, USA Keywords: Amyotrophic Lateral Sclerosis, ALS, SOD1, G94A, mRNA Therapeutics, Computational Biology, Bioinformatics, Python, Genetic Mutations, RNA Therapeutics, AI-Assisted Drug Discovery.